The present Phase 2 clinical study will evaluate the safety and immunogenicity of the immunogenic formulation cGMP rBCG-N-RSV of 100 research hub

Randomized, double-blind, phase 2 clinical trial controlled with conventional Bacillus Calmette-Guérin (BCG) vaccine to evaluate the safety and immunogenicity of a recombinant BCG vaccine that expresses the respiratory syncytial virus (RSV) nucleoprotein (N) (rBCG-N-RSV) in adults over 60 years of age.

This study is testing a new version of the BCG vaccine, designed to protect against both tuberculosis and RSV (a common winter cold virus), in people over 60. We want to see how safe it is and how well it helps the body fight off these infections.